Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)

NCT04456699 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

335

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Olaparib
DRUG: 5-FU
DRUG: Bevacizumab
DRUG: Capecitabine
DRUG: Leucovorin/ levoleucovorin

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]